Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer

Hyun Jeong Oh, Eun Sook Park, Seong Man Kang, Inho Jo, Sung Chul Jung

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH). The accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. Low-phenylalanine diet therapy can prevent irreversible damage if instituted from birth. However, poor compliance with the strict lifelong dietary therapy leads to various neurologic and behavioral problems. To develop a safe and promising gene therapy method for PKU, we investigated whether a recombinant adeno-associated virus could be used as a PAH gene transfer vector to reduce the excessive phenylalanine level in the PKU mouse model. A recombinant adeno-associated virus vector encoding the human PAH gene (rAAV-hPAH), driven by EF1-α promoter, was infused into PAH-deficient mice, Pahenu2, via the hepatic portal vein. Two weeks after injection, the plasma phenylalanine level dramatically decreased to 360 μM in male PKU mice, accompanied by the coat color changing to black. The mean plasma phenylalanine level of untreated PKU mice was 1800 μM. The PAH enzyme activities of treated mice increased to 10-17% of wild-type mice. No signs of liver toxicity were observed after gene transfer. The biochemical and phenotypic corrections were sustained for up to 25 wk (25-wk detection period). In contrast, the treatment was less effective in female PKU mice. These results indicate that recombinant adeno-associated virus vector-mediated gene therapy can be a useful therapeutic candidate for patients with PKU. Further studies are needed to clarify the differences in PKU pathogenesis in males and females, and to explore alternative administration routes besides hepatic portal vein injection.

Original languageEnglish
Pages (from-to)278-284
Number of pages7
JournalPediatric Research
Volume56
Issue number2
DOIs
Publication statusPublished - 2004 Aug 1

Fingerprint

Dependovirus
Phenylketonurias
Phenylalanine Hydroxylase
Phenylalanine
Genes
Hepatic Veins
Portal Vein
Genetic Therapy
Hypopigmentation
Diet Therapy
Injections
Intellectual Disability
Hair
Nervous System
Therapeutics
Color
Parturition
Skin
Liver

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. / Oh, Hyun Jeong; Park, Eun Sook; Kang, Seong Man; Jo, Inho; Jung, Sung Chul.

In: Pediatric Research, Vol. 56, No. 2, 01.08.2004, p. 278-284.

Research output: Contribution to journalArticle

@article{b321f2b47dd747dc8bddf147a781f056,
title = "Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer",
abstract = "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH). The accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. Low-phenylalanine diet therapy can prevent irreversible damage if instituted from birth. However, poor compliance with the strict lifelong dietary therapy leads to various neurologic and behavioral problems. To develop a safe and promising gene therapy method for PKU, we investigated whether a recombinant adeno-associated virus could be used as a PAH gene transfer vector to reduce the excessive phenylalanine level in the PKU mouse model. A recombinant adeno-associated virus vector encoding the human PAH gene (rAAV-hPAH), driven by EF1-α promoter, was infused into PAH-deficient mice, Pahenu2, via the hepatic portal vein. Two weeks after injection, the plasma phenylalanine level dramatically decreased to 360 μM in male PKU mice, accompanied by the coat color changing to black. The mean plasma phenylalanine level of untreated PKU mice was 1800 μM. The PAH enzyme activities of treated mice increased to 10-17{\%} of wild-type mice. No signs of liver toxicity were observed after gene transfer. The biochemical and phenotypic corrections were sustained for up to 25 wk (25-wk detection period). In contrast, the treatment was less effective in female PKU mice. These results indicate that recombinant adeno-associated virus vector-mediated gene therapy can be a useful therapeutic candidate for patients with PKU. Further studies are needed to clarify the differences in PKU pathogenesis in males and females, and to explore alternative administration routes besides hepatic portal vein injection.",
author = "Oh, {Hyun Jeong} and Park, {Eun Sook} and Kang, {Seong Man} and Inho Jo and Jung, {Sung Chul}",
year = "2004",
month = "8",
day = "1",
doi = "10.1203/01.PDR.0000132837.29067.0E",
language = "English",
volume = "56",
pages = "278--284",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer

AU - Oh, Hyun Jeong

AU - Park, Eun Sook

AU - Kang, Seong Man

AU - Jo, Inho

AU - Jung, Sung Chul

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH). The accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. Low-phenylalanine diet therapy can prevent irreversible damage if instituted from birth. However, poor compliance with the strict lifelong dietary therapy leads to various neurologic and behavioral problems. To develop a safe and promising gene therapy method for PKU, we investigated whether a recombinant adeno-associated virus could be used as a PAH gene transfer vector to reduce the excessive phenylalanine level in the PKU mouse model. A recombinant adeno-associated virus vector encoding the human PAH gene (rAAV-hPAH), driven by EF1-α promoter, was infused into PAH-deficient mice, Pahenu2, via the hepatic portal vein. Two weeks after injection, the plasma phenylalanine level dramatically decreased to 360 μM in male PKU mice, accompanied by the coat color changing to black. The mean plasma phenylalanine level of untreated PKU mice was 1800 μM. The PAH enzyme activities of treated mice increased to 10-17% of wild-type mice. No signs of liver toxicity were observed after gene transfer. The biochemical and phenotypic corrections were sustained for up to 25 wk (25-wk detection period). In contrast, the treatment was less effective in female PKU mice. These results indicate that recombinant adeno-associated virus vector-mediated gene therapy can be a useful therapeutic candidate for patients with PKU. Further studies are needed to clarify the differences in PKU pathogenesis in males and females, and to explore alternative administration routes besides hepatic portal vein injection.

AB - Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH). The accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. Low-phenylalanine diet therapy can prevent irreversible damage if instituted from birth. However, poor compliance with the strict lifelong dietary therapy leads to various neurologic and behavioral problems. To develop a safe and promising gene therapy method for PKU, we investigated whether a recombinant adeno-associated virus could be used as a PAH gene transfer vector to reduce the excessive phenylalanine level in the PKU mouse model. A recombinant adeno-associated virus vector encoding the human PAH gene (rAAV-hPAH), driven by EF1-α promoter, was infused into PAH-deficient mice, Pahenu2, via the hepatic portal vein. Two weeks after injection, the plasma phenylalanine level dramatically decreased to 360 μM in male PKU mice, accompanied by the coat color changing to black. The mean plasma phenylalanine level of untreated PKU mice was 1800 μM. The PAH enzyme activities of treated mice increased to 10-17% of wild-type mice. No signs of liver toxicity were observed after gene transfer. The biochemical and phenotypic corrections were sustained for up to 25 wk (25-wk detection period). In contrast, the treatment was less effective in female PKU mice. These results indicate that recombinant adeno-associated virus vector-mediated gene therapy can be a useful therapeutic candidate for patients with PKU. Further studies are needed to clarify the differences in PKU pathogenesis in males and females, and to explore alternative administration routes besides hepatic portal vein injection.

UR - http://www.scopus.com/inward/record.url?scp=3242778717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242778717&partnerID=8YFLogxK

U2 - 10.1203/01.PDR.0000132837.29067.0E

DO - 10.1203/01.PDR.0000132837.29067.0E

M3 - Article

C2 - 15181195

AN - SCOPUS:3242778717

VL - 56

SP - 278

EP - 284

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 2

ER -